Sepsis: Preventing organ failure in sepsis - the search continues
Thomas J Graetz, Richard S Hotchkiss, Thomas J Graetz, Richard S Hotchkiss
Abstract
In a recent trial, levosimendan therapy failed to ameliorate sepsis-induced organ dysfunction or improve the survival of patients with septic shock. The failure of levosimendan and many other potential therapies for sepsis, together with the findings of histopathologic studies, raise questions regarding the pathophysiologic basis of the disorder.
Conflict of interest statement
Competing interests statement
R.S.H. has received grant support from Medimmune, Bristol-Myers Squibb, and GlaxoSmithKline. T.J.G. declares no competing interests.
Figures
Source: PubMed